These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19666395)

  • 1. A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis.
    Dauletbaev N; Fischer P; Aulbach B; Gross J; Kusche W; Thyroff-Friesinger U; Wagner TO; Bargon J
    Eur J Med Res; 2009 Aug; 14(8):352-8. PubMed ID: 19666395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
    Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
    J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
    Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
    Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.
    Balfour-Lynn IM; Klein NJ; Dinwiddie R
    Arch Dis Child; 1997 Aug; 77(2):124-30. PubMed ID: 9301350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency.
    Atkuri KR; Mantovani JJ; Herzenberg LA; Herzenberg LA
    Curr Opin Pharmacol; 2007 Aug; 7(4):355-9. PubMed ID: 17602868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
    Schmitt-Grohé S; Zielen S
    Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
    Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
    Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: Focus on myeloperoxidase.
    Vasu VT; de Cruz SJ; Houghton JS; Hayakawa KA; Morrissey BM; Cross CE; Eiserich JP
    Free Radic Res; 2011 Feb; 45(2):165-76. PubMed ID: 20954832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis.
    App EM; Baran D; Dab I; Malfroot A; Coffiner M; Vanderbist F; King M
    Eur Respir J; 2002 Feb; 19(2):294-302. PubMed ID: 11866009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
    Noone PG; Hamblett N; Accurso F; Aitken ML; Boyle M; Dovey M; Gibson R; Johnson C; Kellerman D; Konstan MW; Milgram L; Mundahl J; Retsch-Bogort G; Rodman D; Williams-Warren J; Wilmott RW; Zeitlin P; Ramsey B;
    Pediatr Pulmonol; 2001 Aug; 32(2):122-8. PubMed ID: 11477729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
    Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
    Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.
    Tirouvanziam R; Conrad CK; Bottiglieri T; Herzenberg LA; Moss RB; Herzenberg LA
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4628-33. PubMed ID: 16537378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study.
    Ordoñez CL; Stulbarg M; Grundland H; Liu JT; Boushey HA
    Pediatr Pulmonol; 2001 Jul; 32(1):29-37. PubMed ID: 11416873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: A meta-analysis of prospective clinical trials.
    Hu J; Zhang Q; Ren X; Sun Z; Quan Q
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):594-9. PubMed ID: 25732608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study.
    Skov M; Pressler T; Lykkesfeldt J; Poulsen HE; Jensen PØ; Johansen HK; Qvist T; Kræmer D; Høiby N; Ciofu O
    J Cyst Fibros; 2015 Mar; 14(2):211-8. PubMed ID: 25458464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
    Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
    Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial.
    Treweeke AT; Winterburn TJ; Mackenzie I; Barrett F; Barr C; Rushworth GF; Dransfield I; MacRury SM; Megson IL
    Diabetologia; 2012 Nov; 55(11):2920-8. PubMed ID: 22935960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.